Fibrocor Therapeutics L.P.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fibrocor Therapeutics L.P.
Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos.
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
Pre-IPO Bridge Biotherapeutics inks major idiopathic pulmonary fibrosis license agreement with Boehringer Ingelheim, marking the biggest single product licensing out deal by a South Korean biotech. The move is poised to further bolster the German firm's leading position in the field and reflects global pharma's increasing interest in IPF.
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.